Eli Lilly

Amgen

Rogers

Merck

Pfizer

Thermo Fisher Scientific

West Pharmaceutical Services

Zealand Pharma

Catalent

Amplify Weight Loss Drug & Treatment ETF

THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.

Roundhill GLP-1 & Weight Loss ETF

Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

Principal Healthcare Innovators Index ETF

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Health Care Covered Call & Growth ETF

SPDR S&P Insurance ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco DWA Healthcare Momentum ETF

Invesco S&P 500 Equal Weight Health Care ETF

SPDR Portfolio S&P 500 Growth ETF

SPDR Portfolio S&P 500 Value ETF

Vanguard Health Care ETF

SPDR S&P Biotech ETF

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?

Finding Opportunity in Unloved Healthcare ETFs

Tema Obesity & Cardiometabolic ETF

Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.

Play These New ETFs to Tap Lucrative Weight Loss Drug Market

On Tuesday, Amplify entered the weight loss ETF space with the launch of the Amplify Weight Loss Drug & Treatment ETF (THNR). THNR operates with a net expense ratio of 0.59%.

Amplify Debuts New Weight Loss Drug ETF

News for Amplify Weight Loss Drug & Treatment ETF ETF (THNR)